Are glucocorticoid-induced osteoporosis recommendations suffi cient to determine antiosteoporotic treatment for patients with rheumatoid arthritis? |
Lee, Joo-Hyun
(Department of Internal Medicine, Inje University Ilsan Paik Hospital)
Cho, Soo-Kyung (Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases) Han, Minkyung (Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases) Kim, Dam (Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases) Bae, Sang-Cheol (Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases) Sung, Yoon-Kyoung (Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases) |
1 | Curtis JR, Westfall AO, Allison JJ, et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid- treated patients. Arthritis Rheum 2005;52:2485-2494. DOI ScienceOn |
2 | Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 1995;54:801-806. DOI ScienceOn |
3 | Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-739. |
4 | Roux C. Osteoporosis in inf lammatory joint diseases. Osteoporos Int 2011;22:421-433. DOI |
5 | van Staa TP, Geusens P, Bijlsma JW, Leuf kens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3104-3112. DOI ScienceOn |
6 | Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E. FRAX and its app lications to clinical practice. Bone 2009;44:734-743. DOI ScienceOn |
7 | Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol 2010;6:82-88. DOI ScienceOn |
8 | Watts NB, Lewiecki EM, Miller PD, Baim S. National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom 2008;11:473-477. DOI ScienceOn |
9 | Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62:1515-1526. DOI |
10 | Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011;22:809-816. DOI |
11 | Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137-1148. |
12 | Compston JE. Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis. Curr Rheumatol Rep 2007;9:78-84. DOI ScienceOn |
13 | Ghazi M, Kolta S, Briot K, Fechtenbaum J, Paternotte S, Roux C. Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids. Osteoporos Int 2012;23:581-587. DOI ScienceOn |
14 | Spector TD, Hall GM, McCloskey EV, Kanis JA. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ 1993;306:558. DOI ScienceOn |
![]() |